[go: up one dir, main page]

ECSP22037660A - Agonistas del receptor npy2 - Google Patents

Agonistas del receptor npy2

Info

Publication number
ECSP22037660A
ECSP22037660A ECSENADI202237660A ECDI202237660A ECSP22037660A EC SP22037660 A ECSP22037660 A EC SP22037660A EC SENADI202237660 A ECSENADI202237660 A EC SENADI202237660A EC DI202237660 A ECDI202237660 A EC DI202237660A EC SP22037660 A ECSP22037660 A EC SP22037660A
Authority
EC
Ecuador
Prior art keywords
receptor agonists
analogs
npy2 receptor
relates
npy2
Prior art date
Application number
ECSENADI202237660A
Other languages
English (en)
Inventor
Soren Pedersen
Albert Brennauer
Charlotte Madsen
Peter Haebel
Stefan Peters
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP22037660A publication Critical patent/ECSP22037660A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2271—Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a análogos de PYY que tienen alanina en la posición 4, lisina en la posición 7, QRY como el extremo del terminal C y un grupo de prolongación de semivida. Los análogos de la invención son solubles a alrededor de pH 6 y 7. La invención también se refiere a composiciones farmacéuticas que comprenden tales análogos de PYY y al uso médico de los análogos.
ECSENADI202237660A 2019-11-11 2022-05-11 Agonistas del receptor npy2 ECSP22037660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19208394 2019-11-11
PCT/EP2020/081513 WO2021094259A1 (en) 2019-11-11 2020-11-09 Npy2 receptor agonists

Publications (1)

Publication Number Publication Date
ECSP22037660A true ECSP22037660A (es) 2022-06-30

Family

ID=68531488

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202237660A ECSP22037660A (es) 2019-11-11 2022-05-11 Agonistas del receptor npy2

Country Status (20)

Country Link
US (3) US20210139548A1 (es)
EP (1) EP4058047A1 (es)
JP (1) JP2023500895A (es)
KR (1) KR20220100925A (es)
CN (1) CN114641303A (es)
AR (1) AR120440A1 (es)
AU (1) AU2020384729A1 (es)
CA (1) CA3156452A1 (es)
CL (1) CL2022001227A1 (es)
CO (1) CO2022006046A2 (es)
CR (1) CR20220206A (es)
DO (1) DOP2022000097A (es)
EC (1) ECSP22037660A (es)
IL (1) IL292601A (es)
JO (1) JOP20220110A1 (es)
MX (1) MX2022005661A (es)
PE (1) PE20221168A1 (es)
PH (1) PH12022551101A1 (es)
TW (1) TWI864155B (es)
WO (1) WO2021094259A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20220110A1 (ar) 2019-11-11 2023-01-30 Boehringer Ingelheim Int ناهضات مستقبل npy2
MX2023001532A (es) 2020-08-07 2023-03-08 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles.
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
EP4638481A1 (en) * 2022-12-21 2025-10-29 Boehringer Ingelheim International GmbH Glp1/gip/npy2 receptor triple agonists
EP4670741A1 (en) 2023-04-28 2025-12-31 Pinotbio, Inc. ANTIBODY-DRUG CONJUGATE IN WHICH ONE OR MORE DRUG-BINDER CONJUGATES ARE LINKED TO AN ANTIBODY AND ITS PREPARATION METHOD

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
EA011860B1 (ru) 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
CA2836267C (en) 2004-12-13 2016-06-21 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
NZ568772A (en) 2005-12-07 2010-05-28 Hoffmann La Roche Truncated analogs of the peptide pYY3-36 that are neuropeptide-2 receptor-agonists
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
EP2158214B1 (en) 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
CN101939022A (zh) 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
FR2934058B1 (fr) 2008-07-15 2010-09-24 Centre Nat Rech Scient Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines
EA020596B1 (ru) 2008-12-15 2014-12-30 Зилэнд Фарма А/С Аналоги глюкагона
US8685919B2 (en) 2008-12-15 2014-04-01 Zealand Pharma A/S Glucagon analogues
US8642541B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
AU2008365556A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
EP2477643A1 (en) 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
US20130096055A1 (en) * 2009-11-13 2013-04-18 Novo Nordisk A/S Long-acting y2 receptor agonists
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
KR20130086343A (ko) 2010-06-24 2013-08-01 질랜드 파마 에이/에스 글루카곤 유사체
ES2664509T3 (es) 2011-06-10 2018-04-19 Novo Nordisk A/S Derivados de pramlintida
SG11201403377QA (en) 2011-12-23 2014-07-30 Zealand Pharma As Glucagon analogues
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
RU2015144632A (ru) 2013-05-02 2017-06-07 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Терапевтические пептиды
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
PT3057984T (pt) 2013-10-17 2018-10-24 Boehringer Ingelheim Int Análogos de glucagon acilados
JP2017503474A (ja) 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
BR112016010643A2 (pt) 2013-11-14 2017-12-05 Keybioscience Ag peptídeo
EP3068795B1 (en) * 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
AU2014350197B2 (en) * 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
EA035791B1 (ru) 2015-03-18 2020-08-11 Зилэнд Фарма А/С Аналоги амилина
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
AR104984A1 (es) * 2015-06-12 2017-08-30 Novo Nordisk As Compuestos selectivos para pyy y sus usos
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
PE20250556A1 (es) 2015-12-31 2025-02-24 Hanmi Pharmaceutical Co Ltd Agonista triple de receptores de glucagon/glp-1/gip
CA3022915A1 (en) 2016-05-03 2017-11-09 The Scripps Research Institute Trkb agonist antibodies for treating neurodegenerative disorders
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
JOP20190095A1 (ar) 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
TW201833131A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
CN108289005B (zh) 2017-01-09 2021-06-29 中兴通讯股份有限公司 信令发送、接收方法及装置
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
TWI749381B (zh) * 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
JOP20220110A1 (ar) 2019-11-11 2023-01-30 Boehringer Ingelheim Int ناهضات مستقبل npy2

Also Published As

Publication number Publication date
CL2022001227A1 (es) 2023-02-03
EP4058047A1 (en) 2022-09-21
TWI864155B (zh) 2024-12-01
IL292601A (en) 2022-07-01
TW202134263A (zh) 2021-09-16
JOP20220110A1 (ar) 2023-01-30
KR20220100925A (ko) 2022-07-18
DOP2022000097A (es) 2022-06-15
PH12022551101A1 (en) 2023-11-13
US20250002544A1 (en) 2025-01-02
US12054525B2 (en) 2024-08-06
AR120440A1 (es) 2022-02-16
CR20220206A (es) 2022-06-16
CO2022006046A2 (es) 2022-05-20
US20210139548A1 (en) 2021-05-13
JP2023500895A (ja) 2023-01-11
US20230340039A1 (en) 2023-10-26
WO2021094259A1 (en) 2021-05-20
PE20221168A1 (es) 2022-07-25
CA3156452A1 (en) 2021-05-20
CN114641303A (zh) 2022-06-17
AU2020384729A1 (en) 2022-04-14
MX2022005661A (es) 2022-09-07

Similar Documents

Publication Publication Date Title
ECSP22037660A (es) Agonistas del receptor npy2
CL2023000357A1 (es) Agonistas del receptor npy2 solubles
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
MX2020006474A (es) Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
BR112022002720A2 (pt) Formulações de conjugados de benzazepinas e usos das mesmas
CL2021003273A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
NZ743489A (en) Controlled-release cnp agonists with low npr-c binding
MX2022006737A (es) Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados.
BR112022006297A2 (pt) Agonistas de receptor de npy2
EA202290107A1 (ru) Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1
EA202192475A1 (ru) Способ получения стабильных пептидных составов
MX2016004660A (es) Composiciones de peptido novedosas.
EA202191511A1 (ru) Составы на основе аналога пептида оксинтомодулина
EA202091375A1 (ru) БИЦИКЛИЧЕСКИЕ ПЕПТИДНЫЕ ЛИГАНДЫ, ОБЛАДАЮЩИЕ СПЕЦИФИЧНОСТЬЮ К EphA2